CSIMarket
 
Insulet Corporation  (PODD)
Other Ticker:  
 
 

Insulet's Customers Performance

PODD

 
PODD's Source of Revenues During the corresponding time, Insulet Corporation recorded revenue increase by 23.35 % year on year, sequentially revenue fell by -13.36 %. While revenue at the Insulet Corporation's corporate clients

List of PODD Customers




for the same period Insulet Corporation recorded revenue increase by 23.35 % year on year, sequentially revnue fell by -13.36 %.

List of PODD Customers





Insulet's Comment on Sales, Marketing and Customers





  News about Insulet Corporation Contracts

Omnipod 5 Bolsters Type 2 Diabetes Care with Enhanced Outcomes and Quality of Life,

Omnipod 5: A Revolution in Type 2 Diabetes Management Demonstrates Promising Clinical Outcomes and Improved Quality of Life'ACTON, Mass.' -- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today unveiled groundbreaking results from its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) pivotal trial for type 2 diabetes. The significant findings were presented at the American Diabetes Association (ADA) 84th Scientific Sessions in Orlando, Florida. This landmark study assessed the efficacy and safety of AID in a diverse cohort of individuals with type 2 diabetes, providing a new beacon of hope for impro...

Insulets Omnipod 5 Sets New Standard for Type 2 Diabetes Management Improving Clinical Outcomes and Quality of Life

Insulet Corporation, the global leader in tubeless insulin pump technology, has made significant advancements in the treatment of type 2 diabetes with its Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The groundbreaking results from the pivotal trial of Omnipod 5 were shared at the American Diabetes Association's Scientific Sessions, showcasing its ability to improve clinical outcomes and enhance the quality of life for individuals with type 2 diabetes.The pivotal trial evaluated the impact of Automated Insulin Delivery (AID) in a diverse group of people with type 2 diabetes, demonstrating remarkable benefits. By leveraging innovative technology, Omnipod 5 allows for personalized and optimized ins...

Insulet Bolsters Growth: A Model of Sustainability and Accessibility in Healthcare Technology

In a significant leap towards responsible business growth, Insulet Corporation (NASDAQ: PODD), the dominant player behind revolutionary tubeless insulin pump technology marketed under the Omnipod brand, has recently published its landmark 2023 Sustainability Report. Crucially, the report underlines the corporation's unfettered commitment to continued sustainability efforts and product accessibility.A comprehensive review of this report reveals impressive strides made by Insulet in consolidating its environmental, social, and governance (ESG) initiatives throughout 2023. It is an upfront disclosure of their relentless pursuit of sustainability, a major driving force in generating substantial value for their s...

Insulet's Omnipod 5 Automated Insulin Delivery System: A Game-Changer for Type 1 Diabetes Management

Insulet Corporation, the leading global provider of tubeless insulin pump technology, has recently released two significant updates regarding their Omnipod 5 Automated Insulin Delivery System (Omnipod 5). These groundbreaking developments include favorable results from a randomized controlled trial (RCT) and CE mark approval for compatibility with Abbott's FreeStyle Libre 2 Plus sensor. Let's delve into the facts and assess their impact on Insulet Corporation.Insulet's OP5-003 Trial Demonstrates Superiority:Insulet Corporation presented encouraging outcomes from its first-ever randomized controlled trial, known as the OP5-003 Trial. This clinical study focused on evaluating the effectiveness of the Omnipod 5...

Insulet's Omnipod 5 Automated Insulin Delivery System: Unveiling Promising Results from Groundbreaking Trial at the 17th International Conference on Advanced Technologies and Treatments for Diabetes

Insulet to Present Results from First Omnipod 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD)ACTON, Mass. - Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod brand of products, is set to present new clinical evidence at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence, Italy from March 6 to 9, 2024. The presentation will focus on the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) and will be simultaneously available online.Insulet is excited to reveal the results of an important milestone in diabetes...












PODD's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Insulet Corporation 14,322.71 1,780.70 234.00 3,500
SUBTOTAL 0.00 0.00 0.00 -


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com